TK210 ELISA universal serum protein biomarker for cancer screening diagnosis...
TK210 ELISA universal serum protein biomarker for cancer screening diagnosis treatment response monitoring and early detection of relapse UNIBIO
The UNIBIO project is a feasibility study for TK210 ELISA – a serum and plasma biomarker for cancer diagnosis and treatment response. Leveraging on the knowledge that cancer cells undergoing rapid growth produce and release into t...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
CVDTEU
Clinical validation of the DiviTum assay in key European mar...
71K€
Cerrado
EDePDAC
Feasibility study for the validation and industrialization o...
71K€
Cerrado
RTC-2017-6271-1
Desarrollo tecnológico para cuantificar en suero un nuevo ma...
405K€
Cerrado
CANDLE
Cancer Diagnosis by Multiplex Protein Epitope Profiling
71K€
Cerrado
PDC2022-133476-I00
ESTUDIO DE VALIDACION Y VALORIZACION EN EL MERCADO DE EPICAR...
148K€
Cerrado
PLEC2021-007892
Plataforma (Oncodeeplasm) para inmunoensayos optoplasmónicos...
336K€
Cerrado
Información proyecto UNIBIO
Duración del proyecto: 1 meses
Fecha Inicio: 2015-09-15
Fecha Fin: 2015-10-31
Líder del proyecto
AROCELL AB PUBL
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The UNIBIO project is a feasibility study for TK210 ELISA – a serum and plasma biomarker for cancer diagnosis and treatment response. Leveraging on the knowledge that cancer cells undergoing rapid growth produce and release into the blood abnormal amounts of protein called thymidine kinase (TK), AroCell has pre-validated a biomarker that quantifies the amount of TK protein directly in the serum in a blood sample. Current cell growth-related biomarkers are measured from tumour tissue, which limits their clinical utility. Recognizing a strong business opportunity, AroCell will propose TK210 ELISA as an easily-deployable and cost-efficient diagnostic and treatment-response test. The key need of clinicians and oncologists is the access to reliable biomarkers for the malignancy potential of cancer at diagnosis and effective monitoring of therapies. The test should make it possible to implement cost-efficient added information for diagnosis and follow-up. In the Phase 1 project, AroCell will perform a feasibility study verifying the clinical and economic viability of the clinical validation to be performed in the Phase 2 project. The EU added value of the project lies in the possibility to improve diagnostic accuracy using a minimally invasive diagnostic procedure based on the ELISA platform that is established within the EU Community.